Medifast [MED] vs Regis [RGS] Detailed Stock Comparison
Medifast
NYSE
Loading...
Regis
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Medifast wins in 8 metrics, Regis wins in 10 metrics, with 0 ties. Regis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medifast | Regis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 42.39 | 0.68 | Regis |
| Price-to-Book Ratio | 0.67 | 0.39 | Regis |
| Debt-to-Equity Ratio | 6.05 | 188.97 | Medifast |
| PEG Ratio | -0.32 | -11.20 | Regis |
| EV/EBITDA | -0.22 | 17.52 | Medifast |
| Profit Margin (TTM) | 0.76% | 58.79% | Regis |
| Operating Margin (TTM) | -1.01% | 7.59% | Regis |
| EBITDA Margin (TTM) | N/A | 7.59% | N/A |
| Return on Equity | 1.73% | 96.56% | Regis |
| Return on Assets (TTM) | 2.88% | 2.25% | Medifast |
| Free Cash Flow (TTM) | $17.02M | $12.45M | Medifast |
| 1-Year Return | -24.13% | 8.39% | Regis |
| Price-to-Sales Ratio (TTM) | 0.32 | 0.34 | Medifast |
| Enterprise Value | $-5.94M | $405.86M | Regis |
| EV/Revenue Ratio | -0.01 | 1.93 | Medifast |
| Gross Profit Margin (TTM) | 72.61% | 36.70% | Medifast |
| Revenue per Share (TTM) | $44 | $89 | Regis |
| Earnings per Share (Diluted) | $0.33 | $43.67 | Regis |
| Beta (Stock Volatility) | 0.88 | 1.77 | Medifast |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medifast vs Regis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medifast | 2.34% | 2.04% | 0.21% | -4.05% | 7.12% | -19.09% |
| Regis | 0.44% | 3.28% | 22.89% | 27.61% | 69.32% | 24.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medifast | -24.13% | -87.77% | -91.52% | -51.52% | -47.23% | 246.29% |
| Regis | 8.39% | 35.69% | -78.87% | -88.68% | 55.03% | -18.76% |
Performance & Financial Health Analysis: Medifast vs Regis
| Metric | MED | RGS |
|---|---|---|
| Market Information | ||
| Market Cap | $155.35M | $74.66M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 147,157 | 10,476 |
| 90 Day Avg. Volume | 150,239 | 22,679 |
| Last Close | $13.99 | $29.58 |
| 52 Week Range | $11.57 - $21.98 | $15.00 - $30.29 |
| % from 52W High | -36.35% | -2.34% |
| All-Time High | $336.99 (May 24, 2021) | $465.40 (Oct 28, 2019) |
| % from All-Time High | -95.85% | -93.64% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.37% | 0.22% |
| Quarterly Earnings Growth | -0.37% | 0.28% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.59% |
| Operating Margin (TTM) | -0.01% | 0.08% |
| Return on Equity (TTM) | 0.02% | 0.97% |
| Debt to Equity (MRQ) | 6.05 | 188.97 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.04 | $76.20 |
| Cash per Share (MRQ) | $15.84 | $6.96 |
| Operating Cash Flow (TTM) | $4.15M | $13.74M |
| Levered Free Cash Flow (TTM) | $10.69M | $10.93M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | $0.00 |
Valuation & Enterprise Metrics Analysis: Medifast vs Regis
| Metric | MED | RGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 42.39 | 0.68 |
| Forward P/E | 46.63 | -11.20 |
| PEG Ratio | -0.32 | -11.20 |
| Price to Sales (TTM) | 0.32 | 0.34 |
| Price to Book (MRQ) | 0.67 | 0.39 |
| Market Capitalization | ||
| Market Capitalization | $155.35M | $74.66M |
| Enterprise Value | $-5,940,794 | $405.86M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.01 | 1.93 |
| Enterprise to EBITDA | -0.22 | 17.52 |
| Risk & Other Metrics | ||
| Beta | 0.88 | 1.77 |
| Book Value per Share (MRQ) | $21.04 | $76.20 |
Financial Statements Comparison: Medifast vs Regis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MED | RGS |
|---|---|---|
| Revenue/Sales | $115.73M | $60.40M |
| Cost of Goods Sold | $31.48M | $38.23M |
| Gross Profit | $84.25M | $22.16M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $-1.26M | $7.29M |
| EBITDA | $2.02M | $9.77M |
| Pre-Tax Income | $526,000 | $2.98M |
| Income Tax | $1.30M | $-115.41M |
| Net Income (Profit) | $-772,000 | $116.49M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MED | RGS |
|---|---|---|
| Cash & Equivalents | $91.72M | $16.96M |
| Total Current Assets | $213.52M | $50.48M |
| Total Current Liabilities | $60.60M | $101.69M |
| Long-Term Debt | $8.45M | $288.97M |
| Total Shareholders Equity | $210.96M | $185.62M |
| Retained Earnings | $176.01M | $101.97M |
| Property, Plant & Equipment | $46.32M | $229.86M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MED | RGS |
|---|---|---|
| Operating Cash Flow | $2.62M | $5.63M |
| Capital Expenditures | $-1.52M | N/A |
| Free Cash Flow | $1.88M | $6.23M |
| Debt Repayment | N/A | $-3.60M |
| Common Stock Repurchase | $-369,000 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MED | RGS |
|---|---|---|
| Shares Short | 2.34M | 113,166 |
| Short Ratio | 14.97 | 4.85 |
| Short % of Float | 0.22% | 0.05% |
| Average Daily Volume (10 Day) | 147,157 | 10,476 |
| Average Daily Volume (90 Day) | 150,239 | 22,679 |
| Shares Outstanding | 10.94M | 2.44M |
| Float Shares | 9.15M | 2.17M |
| % Held by Insiders | 0.03% | 0.14% |
| % Held by Institutions | 0.80% | 0.26% |
Dividend Analysis & Yield Comparison: Medifast vs Regis
| Metric | MED | RGS |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $2.74 | $0.00 |
| 3-Year Avg Dividend Yield | 1.43% | N/A |
| 3-Year Total Dividends | $8.22 | $0.00 |
| Ex-Dividend Date | Jun 26, 2023 | N/A |